344 related articles for article (PubMed ID: 26235195)
1. Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
Bronte G; Passiglia F; Galvano A; Russo A
Expert Opin Biol Ther; 2016; 16(1):1-5. PubMed ID: 26235195
[TBL] [Abstract][Full Text] [Related]
2. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis Inhibitors in NSCLC.
Manzo A; Montanino A; Carillio G; Costanzo R; Sandomenico C; Normanno N; Piccirillo MC; Daniele G; Perrone F; Rocco G; Morabito A
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934120
[TBL] [Abstract][Full Text] [Related]
4. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
5. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
[TBL] [Abstract][Full Text] [Related]
6. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
7. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
[TBL] [Abstract][Full Text] [Related]
8. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapies in the treatment of non-small cell lung cancer].
De Grève J; Decoster L; Van Meerbeek J; Vermeij J; Teugels E; Schallier D
Bull Cancer; 2008 Mar; 95(3):358-64. PubMed ID: 18390417
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapies in non-small-cell lung cancer.
Alshangiti A; Chandhoke G; Ellis PM
Curr Oncol; 2018 Jun; 25(Suppl 1):S45-S58. PubMed ID: 29910647
[TBL] [Abstract][Full Text] [Related]
12. Emerging angiogenesis inhibitors for non-small cell lung cancer.
Malapelle U; Rossi A
Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
[No Abstract] [Full Text] [Related]
13. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
14. The safety of second-line treatment options for non-small cell lung cancer.
Rossi A; Maione P; Santabarbara G; Sacco PC; Casaluce F; Sgambato A; Barzelloni ML; Palazzolo G; Gridelli C
Expert Opin Drug Saf; 2017 Apr; 16(4):471-479. PubMed ID: 28276858
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib, a novel triple angiokinase inhibitor for the treatment of non-small cell lung cancer.
Noonan S; Man Wong K; Jimeno A
Drugs Today (Barc); 2015 Jun; 51(6):357-66. PubMed ID: 26261849
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib (BIBF 1120) blocks the tumor promoting signals of lung fibroblast soluble microenvironment.
Epstein Shochet G; Israeli-Shani L; Koslow M; Shitrit D
Lung Cancer; 2016 Jun; 96():7-14. PubMed ID: 27133742
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
